Le RD. Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes. Diabetes Metab Res Rev. 2007;23:593-9.Le Roith, D. (2007) Insulin glargine and receptor-mediated signalling: Clinical implications in treating type 2 diabetes. Diabetes/ Metab. Res. Rev...
Nursing Implications and Procedure Pretest Positively identify the patient using at least two unique identifiers before providing care, treatment, or services. Patient Teaching:Inform the patient this test can assist in the diagnosis and management of type 1 diabetes. ...
The study aim was to identify key factors associated with the health-related quality of life (HRQOL) of patients with type 1 diabetes mellitus (T1DM) treated with neutral protamine Hagedorn (NPH) insulin or human insulin analog glargine (IGLA). METHODS. We conducted two cross-sectional studies ...
These analogs have been formulated into either bolus insulin analogs (lispro, aspart, and glulisine) or basal insulin analogs (glargine, detemir, degludec, and icodec) (Table 2). Table 1. Insulin analogs, their onset time, time to peak serum concentration, and duration of drug action. ...
Detemir and glargine, the two long-acting insulin analogs available in the United States, have relatively flat time-action profiles and more closely mirror the physiologic action of basal insulin than NPH insulin, which peaks at 6 to 14 hours. As the therapeutic effect of detemir and glargine ...
The use of basal insulin is widely recommended to expedite the transition to subcutaneous insulin therapy from intravenous insulin therapy and to maintain glucose control;4 a long-acting analog, such as insulin glargine or insulin detemir, may be the best option.86 The long-acting formulations can...
Biosimilar Glargine Insulin: Implications for Prescribers and Patientsdoi:10.1016/j.nurpra.2016.11.022SDOSJournal for Nurse PractitionersPereira K. Biosimilar Glargine Insulin: Implications for Prescribers and Patients. J Nurse Pract 2017; 13 (3):236-7....
Developmental BiologyMarra LP, Araujo VE, Oliveria GCC, Diniz LM, Guerra Junior AA, de Assis Acurcio F et al. The clinical effectiveness of insulin glargine in patients with type 1 diabetes in Brazil: findings and implications. J Comp Eff Res. 2017 Sep;6(6):519-527....
The cost implications of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial were evaluated using a prespecified analysis plan. Purchasing power parity-adjusted country-specific costs were applied to consumed healthcare resources by participants from each country. Subgroup analyses ...